Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 5/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271701 | 0.91 | VEGFA (0.60) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL30402716 | 0.90 | VEGFA (0.59) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL1772095 | 0.90 | VEGFA (0.59) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL17005917 | 0.89 | VEGFA (0.60) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL17005979 | 0.88 | VEGFA (0.56) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL272504 | 0.88 | VEGFA (0.62) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL17005952 | 0.86 | VEGFA (0.55) | VEGFAEGLN1LMNATP53MAPT | |
| SCHEMBL271566 | 0.86 | VEGFA (0.65) | VEGFAEGLN1TP53MAPTKMT2A | |
| SCHEMBL1868340 | 0.85 | VEGFA (0.63) | VEGFAEGLN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL271286 | 0.85 | EGLN1 (0.67) | VEGFAEGLN1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARNER CHILCOTT COMPANY, LLC | 2010-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | VEGFA 3152/4885EGLN1 776/4885LMNA 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.